As an Am­gen's PhI­II car­dio plan takes shape, Roy­al­ty Phar­ma snags a stake in fu­ture sales

A few days af­ter Am­gen chart­ed a Phase III map for an up-and-com­ing car­dio drug, the biotech be­hind its de­vel­op­ment has de­cid­ed to cash out.

Ar­row­head Phar­ma­ceu­ti­cals an­nounced Wednes­day morn­ing that it has sold its roy­al­ty stake in ol­pasir­an, a siR­NA drug de­vel­oped in-house, to Roy­al­ty Phar­ma for $250 mil­lion in up­front cash, plus an­oth­er $160 mil­lion in mile­stones. The sale rep­re­sents all of Ar­row­head’s roy­al­ties in the pro­gram, though the biotech kept the rights to pos­si­ble down­stream mile­stones from Am­gen, worth up to an­oth­er $400 mil­lion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER